DaVita Inc. (DVA) Earnings Call Transcript & Summary
February 2, 2026
What were the key takeaways from DaVita Inc.'s February 2, 2026 earnings call?
In the fourth quarter of 2025, DaVita Inc. (DVA:US) reported adjusted operating income of $586 million and adjusted earnings per share (EPS) of $3.40, aligning with expectations. For the full year, adjusted operating income reached $2.094 billion, while adjusted EPS from continuing operations was $10.78. Management provided optimistic guidance for 2026, projecting adjusted operating income between $2.085 billion and $2.235 billion, reflecting a 3.2% growth at the midpoint, and adjusted EPS of $13.60 to $15, indicating a 33% increase at the midpoint, exceeding long-term targets.
What topics did DaVita Inc. cover?
- Integrated Kidney Care (IKC) Profitability: DaVita achieved its first profitable year in IKC slightly ahead of schedule, reporting $22 million in adjusted operating income for the full year. CEO Javier Rodriguez stated, "This milestone reinforces... our dedicated IKC caregivers are delivering on the promise of value-based care by keeping patients healthier and out of the hospital."
- Revenue Per Treatment Growth: Revenue per treatment (RPT) grew approximately $12 sequentially in Q4, driven by aged receivables resolution and improved yield. Joel Ackerman noted, "Fourth quarter growth was the result of... normal rate increases and improved yield."
- Guidance for 2026: Management raised guidance for 2026, expecting adjusted operating income between $2.085 billion and $2.235 billion and adjusted EPS of $13.60 to $15. This guidance reflects confidence in operational performance and capital allocation strategies.
- Challenges in Treatment Volume Growth: DaVita anticipates continued pressure on treatment growth due to elevated mortality rates and the expiration of enhanced premium tax credits. Management acknowledged, "We're managing 2 near-term financial headwinds... continued pressure on treatment growth driven by elevated mortality."
- Free Cash Flow and Capital Allocation: DaVita expects to generate free cash flow between $1 billion and $1.25 billion in 2026, despite a $200 million investment in Elara Caring. Joel Ackerman stated, "We expect this to contribute positively to our other income line."
What were DaVita Inc.'s February 2, 2026 results?
- Adjusted Operating Income: $586 million (vs $586 million est, inline)
- Adjusted EPS: $3.40 (vs $3.40 est, inline)
- Full Year Adjusted Operating Income: $2.094 billion (vs $2.09 billion est, beat)
- Full Year Adjusted EPS: $10.78 (vs $10.70 est, beat)
- 2026 Adjusted Operating Income Guidance: $2.085 billion to $2.235 billion (reflects 3.2% growth at midpoint, raised)
- 2026 Adjusted EPS Guidance: $13.60 to $15 (reflects 33% growth at midpoint, raised)
DaVita's strong Q4 results and optimistic guidance for 2026 signal a positive outlook for the company, particularly with the profitability of its IKC program and growth in international operations. However, challenges related to treatment volume and mortality rates pose risks that investors should monitor closely. The upcoming year will be critical for assessing the effectiveness of management's clinical initiatives and capital allocation strategies.
Earnings Call Speaker Segments
Nic Eliason
executiveThanks for joining us for the call covering our fourth quarter. My name is Nic Eliason, and I serve as Group Vice President of Investor Relations. With me on the line are our CEO, Javier Rodriguez, and our CFO, Joel Ackerman. I want to point out that we might present forward-looking statements on this call as defined under the federal securities laws. Known and unknown risks and uncertainties apply to all such statements, and those factors could lead to actual results differing materially from what the forward-looking statements describe. If you want more information about these risks and uncertainties, we direct you to the fourth quarter earnings press release along with our SEC filings — this includes our latest annual report on Form 10-K, every subsequent quarterly report on Form 10-Q, and any other later filings we submit to the SEC. The forward-looking statements we make rest on information available to us at present, and we have no intention and take on no obligation to revise them, unless the law requires it. We also want to remind everyone that certain non-GAAP financial measures will be addressed on this call. You can find a reconciliation of those non-GAAP measures against the closest comparable GAAP financial measures in the earnings press release, which has been furnished to the SEC and can be accessed on our website. At this point, I'll hand things over to Javier Rodriguez.
Javier Rodriguez
executiveThanks, Nic. Hello, everyone, and I appreciate you being on today's call. Looking at 2025, this past year stands as the most recent proof of what sets apart our capabilities, our strategy, and our platform. We carried it out with discipline, tackled obstacles directly, and came through on the commitments we made at the start of the year. Meanwhile, we keep putting money into improving patient care and driving growth in future years. Because of that, we're in a strong spot for 2026 and past it, with chances to produce clinical and financial outcomes in line with our long-standing track record and guidance. Today, I'll go over our Q4 results, offer perspective on our clinical strategy, and finish with 2026 guidance. But before anything else, as I always do, I'll begin with a clinical highlight. This quarter, I'd like to focus attention on the clinical results from our Integrated Kidney Care, or IKC, programs. Patients cared for through our IKC models consistently get better outcomes than the wider dialysis population. Those in our IKC programs are 35% more likely to begin dialysis with a permanent vascular access, which brings a better patient experience along with costs that are 3x lower over the first 180 days of dialysis. IKC patients also have fewer bloodstream infections, reach higher vaccination rates, and are more inclined to select home dialysis. On top of that, we observe more than 10% improvement in treatment adherence, with fewer missed treatments. Above all, these outcomes produce what counts most: a better quality of life, with fewer hospitalizations. Moving to our fourth quarter performance, we turned in results consistent with what we expected. As we anticipated, revenue per treatment sped up during the quarter along with strength in IKC. This was partly offset by health benefit costs that came in higher than expected. For the entire year, we hit adjusted operating income and adjusted earnings per share in the upper half of our guidance range, even with the effect of a cyber incident on our U.S. dialysis business. Let me say a bit more about how IKC performed. As we've mentioned before, we look at IKC results on a full-year basis because quarterly swings come from the timing of revenue recognition. Thinking back to our Capital Markets Day in 2021, we laid out a five-year path toward IKC profitability by 2026. Our approach centers on sustainable contracts, physician partnership, and a scalable care model backed by technology. With full-year 2025 results, we're reporting our first profitable year in IKC, which is slightly ahead of schedule. This milestone reinforces two key learnings. First, our hands-on clinical models work. As shown in the outcomes I mentioned earlier, our dedicated IKC caregivers are fulfilling the promise of value-based care by keeping patients healthier and out of the hospital. Second, we've demonstrated there's a viable business model that benefits our patients, benefits the healthcare system, and can create value for DaVita and our partners. The business will keep evolving over time alongside shifts in government policy, competitive dynamics, and innovation. Taking 2025 as our baseline, our expectation is to generate an additional $20 million in IKC operating income growth during 2026. Zooming out across the company, meaningful opportunities lie ahead, and we believe DaVita holds a distinctive position to capture them. Before I get into those opportunities, some background on the road we've traveled so far is worth sharing. Across the last five years, we confronted a broad set of obstacles — everything from macro developments such as the global pandemic and inflation to supply chain disruption and a cyber incident — and despite all of it, we met our multi-year commitments. We delivered high-quality care to our patients, established a strong foundation for what comes next, and produced compound annual growth consistent with our long-term target for adjusted operating income and adjusted EPS; that performance speaks to our teammates' determination and the resilience built into how we operate; it also bolsters our confidence as we confront the opportunities and challenges that lie in front of us. Two near-term financial headwinds are currently being managed: ongoing pressure on treatment growth stemming from elevated mortality, plus the revenue per treatment effect caused by enhanced premium tax credits expiring. Despite these headwinds and the reality of challenges we cannot yet foresee, our confidence in sustaining a track record of profit growth remains intact; that confidence begins with the single most important driver of our long-term success: an unwavering commitment to clinical excellence. A set of targeted initiatives is being executed, aimed at improving patient care, lowering mortality and missed treatment rates, and in the end supporting stronger treatment volume growth. Four specific examples are worth highlighting. The first is vaccination; for many years we maintained flu vaccination rates above 90% among our patients and clinical teammates, and we're striving to get back to that benchmark. Patients of ours vaccinated early in this flu season demonstrated a 9% lower risk of hospitalization and a 27% lower risk of mortality relative to peers who were not vaccinated. Shielding our vulnerable patients from the flu, COVID, and pneumonia is a clinical imperative. The second is GLP-1 adoption and adherence. Evidence is mounting that GLP-1s can lower major adverse cardiac events and mortality for many dialysis patients. We're working actively alongside physicians to help our patients navigate the clinical, operational, and financial complexities surrounding these drugs. The third is pushing dialysis technologies forward to remove middle molecules. Innovations like medium-cutoff dialyzers and hemodiafiltration make it possible to clear a wider range of toxins from the body during treatment. Such technologies help patients recover faster following dialysis and hold promise for cutting mortality by as much as 20% or more. Finally, we announced today a strategic clinical partnership with Elara Caring, a leading home care provider, to build an ESKD-focused offering. This model reaches across Elara's skilled home health, personal care, and hospice service lines, and it's designed to reduce hospitalizations and missed treatment rates while enhancing the overall patient experience. Joel will share more detail on the investment we're making alongside this strategic partnership. Taken as a whole, these clinical programs show how putting patients at the center of what we do ties straight into our business goals. Through better quality of life, fewer hospital stays, and stronger clinical results, we still believe we are heading back toward volume growth of no less than 2%. At the same time, we stay sharply focused on expenses and innovation so we can operate more efficiently, keep U.S. dialysis margins sustainable, and produce lasting financial results; against that background, we have confidence in our capacity to grow adjusted operating income across the coming three years in line with our long-term target of 3%-7%; when it comes to adjusted EPS, given our present capital allocation program and setting aside the drag from what we're investing in Mozarc, we see room to surpass our long-term adjusted EPS guidance of 8%-14%. All of this, taken together, strengthens our capacity to create enduring shareholder value and remain the leader in kidney care. My remarks will close with the guidance we're giving for 2026. We anticipate adjusted operating income in the range of $2.085 billion-$2.235 billion, which equals 3.2% growth at the midpoint. For adjusted earnings per share, our guidance is $13.60-$15.00 even, which reflects 33% growth at the midpoint. That guidance is above our long-term EPS targets, which mirrors our expectation for yet another year of robust operating performance along with the compounding advantages of our capital allocation strategy. Last, we anticipate free cash flow of between $1 billion and $1.25 billion. I'll hand things over now to Joel, who will walk through our financial performance and outlook in greater detail.
Joel Ackerman
executiveThanks, Javier. To start, I'll walk through some specifics on what we saw in the fourth quarter and for the full year of 2025, and after that I'll give you a thorough look at how we're thinking about 2026 guidance. Our adjusted operating income for Q4 came in at $586 million, which lifted the full-year figure for adjusted operating income to $2.094 billion. On adjusted earnings per share from continuing operations, Q4 landed at $3.40, while the full-year number for adjusted EPS from continuing operations reached $10.78. Free cash flow during Q4 totaled $309 million, pushing free cash flow for the entire year to slightly more than $1 billion. Beginning with U.S. dialysis, treatments were down roughly 20 basis points compared with the fourth quarter of 2024. Even though growth in our total patient census across the quarter matched what we had anticipated, the gain in census came mostly toward the end of the period. Across the full year, U.S. treatments fell 1.1% compared with 2024, which matched the expectations we laid out on the Q3 earnings call. Moving on, revenue per treatment growth picked up in Q4, just as we expected, rising by about $12 on a sequential basis. Four main drivers produced that fourth quarter growth. To begin, aged receivables were resolved in a way that lined up with what we projected on the Q3 call. Next, we saw standard rate increases along with better yield. Third, private pay mix ticked up modestly following a decline in the third quarter. And last, RPT got a boost from the usual seasonal effect of flu vaccines. For the full year, RPT came to roughly $410, which is a 4.7% increase for the year. When you're considering RPT for the first quarter of 2026, remember that Q1 carries a customary headwind of $5 or more in RPT tied to patient responsibility amounts at the start of the year. Patient care costs per treatment rose by about $6 sequentially. That increase came mainly from seasonal factors, among them health benefit costs and supply costs running higher. PCCs per treatment ended the year up 5.9% over 2024, close to the upper end of our revised range of expectations, yet still below our initial guidance for the year. Keep in mind that roughly half of the year-over-year rise in PCCs came from binders in the bundle. Now to our other segments: international adjusted OI reached $21 million, which brought full-year adjusted operating income to $114 million; that speaks to solid operating performance in our international business, since we achieved positive organic growth and brought the recent Latin America acquisitions into the fold. In IKC, as Javier mentioned, we achieved our first profitable fiscal year. For the fourth quarter, adjusted operating income came to $46 million, while the full-year figure was $22 million. Every one of the three businesses within IKC delivered strong results, and year-end reconciliations related to our 2024 performance produced shared savings revenue that exceeded our projections. Turning to how we deploy capital: during Q4, we repurchased 2.7 million shares, and an additional 1.7 million shares have been bought back since the quarter ended. As is typical, a portion of those purchases came from Berkshire Hathaway pursuant to the publicly filed repurchase agreement we have, which uses a formula to hold Berkshire's stake at no more than 45%. Across all of 2025, we repurchased slightly fewer than 13 million shares, at a cost of about $1.8 billion. We closed out the year with a leverage ratio of 3.26 x consolidated EBITDA. That's below the third-quarter figure and right in the middle of our targeted 3x-3.5 x band. With that said, let me turn to 2026. As Javier noted, the midpoint of our adjusted operating income guidance is $2.16 billion. For U.S. dialysis, the assumptions baked into that midpoint are as follows: treatment volume should be roughly level with 2025, and that figure assumes a flu impact comparable to the 2023 to 2024 season. We've assumed no improvement from non-flu mortality, despite the fact that, as Javier outlined, we have several initiatives in motion aimed at actively reducing mortality among our patients. On the admissions side, we're modeling 2026 as basically the same as 2025, setting aside what the cyber incident did. To make quarter-by-quarter treatment modeling easier, the press release has a table showing normalized treatment days for each quarter; it accounts for both the treatment-day mix and holiday shifts, so it's the best figure to use when projecting quarterly treatments. As an example, Q1 2026 shows a year-over-year headwind in normalized treatment days, and that's the reason we expect U.S. dialysis treatment volume growth to be negative versus last year in this year's first quarter. Now to RPT. We're projecting 1%-2% growth for 2026. The primary factor behind that is the usual rate increases. There's also a projected $40 million hit we're expecting from exchange plan enhanced premium tax credits lapsing, though that's for the most part canceled out because the $45 million drag from the cyber incident in 2025 goes away. For U.S. dialysis costs overall, our expectation is growth of 1.25%-2.25%, with the main drivers being the usual wage rate bumps plus G&A investments, and that's partly offset by lower depreciation and amortization. When you put all of that together, at the midpoint of our guidance, adjusted operating income for the U.S. dialysis business comes out roughly 1.5% higher. And sitting inside the midpoint of our adjusted OI guidance range is also an assumption that IKC and international each add about 1% to enterprise-adjusted OI growth. Taken together, what we're seeing lines up with the guidance we've set: adjusted operating income growing 3.2% at the midpoint of the range compared with 2025. On seasonality, roughly 20% of the full-year guidance should land in the first quarter's adjusted operating income — that's around $430 million at the midpoint. Moving beneath the operating income line, we're looking at about $10 million of positive other income across the year. That's a meaningful improvement on a year-over-year basis for this line item, and it comes because there are no further losses tied to our Mozarc investment — we've now recognized cumulative losses matching what we put in. Versus 2025, we expect debt expense to come down by $20 million to $40 million. The year-over-year drop in interest rates is what's behind this, coming from both the rate decline itself and the repricing and refinancing deals we did, which brought spreads down. Our expectation is that non-controlling interest lands at about 16% of U.S. dialysis OI, and for the effective tax rate, we're targeting a range of 24.5% to 26.5%. On capital allocation, to build on Javier's comments, we've announced the signing of a minority investment of roughly $200 million alongside a majority investment from Ares Private Equity Funds, aimed at acquiring Elara Caring. Assuming the deal closes, expected around mid-year, we look for it to contribute positively to our other income line. Beyond that, we'll keep buying back shares consistent with our usual framework, while taking into account our liquidity, our leverage, and where our stock trades relative to how we see intrinsic value. Just to remind everyone, a sizable chunk of those repurchases will keep flowing through direct purchases from Berkshire Hathaway under our existing repurchase agreement. At the midpoint of the range, our 2026 adjusted EPS guidance sits at $14.30; there are no unusual or non-recurring items baked into that, and it's a solid base for modeling EPS going forward. Looking at 2026, our guidance represents a 33% jump over the prior year. Two familiar factors account for that: increased operating income and fewer shares outstanding, plus the fact that the drag from our portion of Mozarc's losses, which came up earlier, will no longer be there. Finally, regarding free cash flow, the midpoint for 2026 guidance sits at $1.125 billion, reflecting a business that's resilient and a disciplined approach to deploying our capital resources. That concludes what I had prepared to say today. Operator, we're ready to take questions.
Kevin Fischbeck
analystGreat, thanks. I was hoping to hear a bit more detail on what was said regarding, I suppose, how confident you are about returning to volume growth above 2%. Clearly, the figure you're targeting in the 2026 guidance is somewhat higher than what you had in 2025, yet it remains a long way under that 2%; so is this purely a matter of delivering on mortalities, or are there other factors you're referring to that underpin that confidence?
Javier Rodriguez
executiveYes, Kevin, it's Javier here. Thanks for raising that. What it comes down to is a clinical story. If you look back to the period when this industry experienced its strongest growth, a lot of folks believed it was the incidents. But in truth, it was a clinical story the whole way through as well, which means mortality kept getting better each year. Reaching that 2% requires assuming that the items we laid out in our prepared remarks actually happen. Naturally, we believe there's a delay between carrying out everything clinically and seeing the complete impact. Our expectation is that benefits begin to appear in roughly 2 years' time, and the complete impact would likely be visible around 2029.
Kevin Fischbeck
analystAll right. Good to know when that's happening. I'm blanking. You provided certain guidance ranges spanning multiple years. Did you mention 3 years, or was it 5 years, for those operating income and earnings per share remarks?
Javier Rodriguez
executiveWe never specified a particular year, though our thinking is on roughly a 3-year horizon.
Kevin Fischbeck
analystAll right. Then my final question concerns the free cash flow figure. My understanding, I suppose, is that this amount — the $1.125 billion — comes before the $200 million investment. So when considering share buybacks, should we subtract $200 million from it to determine how much more capital could be deployed, or are you factoring in some different adjustment?
Joel Ackerman
executiveYes, Kevin, that is indeed the correct interpretation. I would also mention that the leverage level serves as a good starting point, since with EBITDA growth we ended up squarely in the middle of the range, as you can see. Had we not raised leverage, we would have landed in the lower half of the range. That is therefore another point to keep in mind when determining the appropriate figure to use for share repurchases.
Kevin Fischbeck
analystAll right. So aside from that $200 million, no other clear place to deploy capital stands out as the probable next move?
Joel Ackerman
executiveCorrect.
Kevin Fischbeck
analystOkay. Great. Thank you.
Javier Rodriguez
executiveThank you.
Andrew Mok
analystHello, and thank you for the detail regarding the 2026 guidance. Could you assist us in grasping how skipped sessions and death rates moved across the fourth quarter? Also, have you managed to establish any link or cause-and-effect relationship involving those two things as you have investigated this matter more deeply? Thanks.
Joel Ackerman
executiveYes. There is not really anything worth pointing out about mortality in that period. Missed treatments rose, though an increase in skipped sessions during Q4 is what you would normally expect. When examining missed treatments for Q4 2025, you would not observe a significant gap compared with missed treatments in Q4 2024. There is little variation when comparing one year to the next. According to our clinical team, a correlation definitely exists between the rate of missed treatment and mortality, yet a certain delay separates those two metrics.
Andrew Mok
analystThank you. Could you elaborate further on what you anticipate regarding the ACA headwind across this year, and perhaps share how open enrollment came in relative to what you had projected, plus what degree of attrition you foresee going forward? Thanks.
Joel Ackerman
executiveMy apologies, Andrew. I didn't catch the beginning of what you asked.
Andrew Mok
analystCould you provide additional specifics about the anticipated timing pattern for the ACA headwind across this year, and perhaps share thoughts on open enrollment—how it compared with what had been expected—plus what magnitude of attrition you foresee for that ACA enrollment over the course of the year? Thanks.
Joel Ackerman
executiveThanks, Andrew. Regarding the figure we provided, we stated roughly 40 million during this year, 70 million in the following year, and 10 million in the year after. What's actually happening is that we're observing the same thing you are across the wider market: open enrollment has come in above what either CBO or we had projected. Everyone is now waiting for the true figure, which at this moment means we're counting plan selection or plan enrollment. After that, naturally, folks are attempting to determine what plan payment will look like in order to gauge what the yield will be. We possess no extra insight beyond whatever you or the marketplace already has concerning what that will turn out to be, given that this marks the first occasion these enhanced premium tax credits have disappeared. Even so, up to now it has proven more resilient than anticipated. We'll know more once bills begin arriving and we see whether people pay. We'd note that our patients, throughout the pandemic and in other periods, given how sick they are and how much they require the healthcare system, are quite sophisticated when it comes to grasping their insurance needs. Consequently, on average, they'll make a special effort to remain insured. That's the reason on the prior call we mentioned there were essentially two groups: our existing patient population, which we believe will prove more resilient, and then the incoming population, which is basically, at present, a CKD population that may not place as much value on insurance as somebody whose kidneys have already failed; that's why the figure increases over time. But clearly we'll be monitoring it through the quarter, and we'll find out once those payments take effect.
Andrew Mok
analystThanks. Could I ask one more thing about that? Do you know roughly what portion of your ACA members get help paying premiums? Appreciate it.
Joel Ackerman
executiveNo, I don't, since clearly there are numerous buckets involved, ranging from the enhanced premium tax credits all the way to the standard ones. You're dealing with income brackets and various other factors. I haven't separated that out any further.
Andrew Mok
analystOkay. Thank you.
Joel Ackerman
executiveThank you.
Justin Lake
analystThank you. Morning, everyone. A few items. To start, regarding our capacity to counterbalance the FX drag using the favorable swing — or really the fact that the cyber-related drag from 2025 won't repeat. As I recall, when you last addressed this, the cyber drag in the current year, though it did damage Q2, got covered by improved collections, meaning it wouldn't end up being as sizable a favorable swing as it could have been in 2026. Is my memory faulty there, or have you identified additional efforts on the reimbursement front?
Joel Ackerman
executiveRight. Let me attempt to break down each component for you, Justin. We flagged a $70 million drag tied to cyber; $25 million of that reflects volume, and the bulk of it repeats since it's simply lost census that we won't recover during 2026. The remaining portion was $45 million, which came as an RPT drag. Our view is that this RPT drag gets balanced out in 2026 essentially through the enhanced premium tax credit drag. Consequently, you won't observe a year-over-year growth issue in RPT, since each year carries a $40 million-$45 million negative. As for several of the other items we flagged, especially concerning Q4 and the settling of certain older claims, there's essentially nothing during the year worth flagging on that front. We settle older claims annually. In hindsight, the 2025 figure is about equal to what appeared in 2024. For 2026, our expectation is that it will be comparable to 2025. I wouldn't flag that as out of the ordinary in any year. What stood out as out of the ordinary was how concentrated things were in Q4 of 2025, which explains why we flagged it during the prior quarter.
Justin Lake
analystUnderstood. Now, turning back to IKC, could you provide additional detail regarding the factors behind the outperformance in 2024 compared with what you had booked before, and how confident you are that this can be sustained and expanded going forward?
Javier Rodriguez
executiveAbsolutely. I'll take that question, Justin — this is Javier. There are a few items we've discussed concerning IKC; so, a brief administrative note: you need to examine it on an annualized basis since it fluctuates quite significantly from quarter to quarter. We break it down into three buckets. The first is dollars under management. You can regard that as volume. And that has remained fairly level; we mentioned this during the prior call. Second, the cost of the model of care along with the G&A cost, where we've managed to keep things steady. And then the third bucket, which is shared savings; within that, naturally, there is contracting and performance related to the value you're adding to the system. Regarding the 2024 reconciliation, we performed better in that shared savings component I just referenced. Is that useful to you?
Justin Lake
analystRight. So in what way did you outperform? Did inpatient admissions drive it, or outpatient? I'm just interested in a bit more detail there, plus why you're confident that figure will keep up at that pace, considering how big the beat was?
Joel Ackerman
executiveRight. Well, honestly, plenty of small factors are at play: managing medications, care transitions, breaking the patient population into segments, reaching patients sooner; we've got fresh interventions and protocols. Naturally, one challenge in this line of business is pinning down precisely what made the difference. Instead, the portfolio overall is delivering, which is why we were at ease announcing an extra +$20 million for 2026.
Justin Lake
analystGot it. Thanks.
Joel Ackerman
executiveThank you.
Nic Eliason
executiveAppreciate it. Just a quick note — that's star one if you'd like to pose a question. A.J. Rice from UBS, your line is open.
AJ Rice
analystThank you. Hello, everyone. To start, there's been plenty of conversation, and even speculation, regarding your IKC business—specifically around whether patients with CKD are being managed more effectively and better. And clearly, there's also talk concerning certain medications that might make a difference. So I was curious: with someone who has kidney disease, what are you observing when it comes to progression of the disease, the timeframe until dialysis is needed, and are you finding that they remain on dialysis for a longer period, or when do you expect any of this to show an effect?
Joel Ackerman
executiveYes. I appreciate the question. The truth is, nothing has changed as far as what we've observed, though as we've discussed, you'd expect that to require some time. Regarding those drugs, they aren't magical, and instead, you need to be taking them for a while before the impact you're describing occurs. So at this point, it's too soon to say. And once more, we've been overseeing these CKD populations for only about 5 years; so it will take more time to become clear.
AJ Rice
analystAll right. Perhaps a quick follow-up regarding the Elara Caring investment. What's the right way to view it? Is this purely a financial move on your end? Will you be involved operationally in ways that could change things for you? Could you give us a bit more detail about what's happening there?
Javier Rodriguez
executiveOf course. There are two components to our investment thesis. First, naturally, we need a solid capital return on that $200 million; we intend to stay disciplined. In our view, it's a well-sized investment, and we want strong capital returns from it. The second component involves benefiting our patient population. About 25% of our population utilizes home health; and through a specialized kidney protocol, we believe we can lower hospitalization and readmissions and then, naturally, work toward cutting missed treatments; so it ties back into this entire loop of striving to do more for our patients while they're with us in our clinic and now beyond the clinic.
AJ Rice
analystOkay. Thanks a lot.
Joel Ackerman
executiveThank you.
Nic Eliason
executiveThanks. Deutsche Bank's Peter Chickering is the following participant in the queue. Sir, your line is now live.
Peter Chickering
analystHi there. Good afternoon, and thanks for taking my questions. Could you spend a moment on the international business — how should we think about top-line growth there, whether it comes from M&A or organic, and how should we think about margins in that segment?
Joel Ackerman
executiveYeah. On international, in general, I'd view growth at both the top line and the bottom line as 50% M&A and 50% organic. Our expectation is that margins keep improving as they leverage the fixed overhead, both at the international level and in the existing market; so international has proven to be a good business for us, a relatively consistent performer, and a contributor of about a point to OI growth over the last few years; and we're expecting more of the same in 2026.
Peter Chickering
analystAll right, and next I want to pose Justin's IKC question in a slightly different way. When you consider the losses recorded during 2022, 2023, and 2024 — please bring us up to speed on those again — why ought we to anticipate that the pace of improvement will slow considerably in 2026? Given how much the losses have narrowed as scale has been achieved, it strikes me as odd. So I'm wondering why we wouldn't witness those benefits expanding at the sort of levels observed across the past couple of years.
Joel Ackerman
executiveYeah. Well, your arithmetic checks out. Going back across those 3 years, OI has improved by an average of roughly $40 million-$50 million annually. At this point we're flagging that this will decelerate. It's simply something that happens naturally once a business matures and grows larger. The chance to keep pushing margins higher just becomes smaller. A high-margin business isn't what we anticipate here. So at present, $20 million per year feels like a comfortable place for us to land regarding its contribution to OI growth.
Peter Chickering
analystAll right. Then the final thing I have is regarding new starts. I believe you mentioned new starts during Q4 and that they were weighted toward the back end. Yet when you consider new starts for 2026, what's your approach to modeling them? And more specifically, how would you separate the payer mix for those new starts compared with earlier years when it comes to commercial, HIX, or government patients? Thanks.
Javier Rodriguez
executiveYeah. So for next year, we aren't flagging any significant shift in new starts, which is similar to mortality and, to a degree, missed treatment rates. Once we observe improvement in those areas, we'll begin flagging them; but in the meantime, flattish is something we're comfortable with. As for mix, look, new patients have consistently carried a commercial mix above that of the average patient. It's simply the natural progression of a patient as they age. They tend to move toward Medicare. Going forward, I don't foresee any alteration to that pattern.
Peter Chickering
analystAll right, so I want to be completely clear on this — the new starts we're observing arrive with the very same commercial mix that has been present for the past several years, roughly speaking. Thanks.
Javier Rodriguez
executiveYes. The single exception being what's happening with HIX, which is shifting. Aside from that, no additional new dynamic stands out to me.
Peter Chickering
analystGreat. Thanks so much.
Ryan Langston
analystThanks. About your comments on the flu vaccine and the prepared remarks — were you pointing to an actual shift in vaccination rates this fourth quarter compared with other fourth quarters, or was it more about seasonal patterns or sequential seasonality?
Javier Rodriguez
executiveWhat I think we stated during the opening remarks is that at our peak, we reached the 90th percentile, and our goal was to return to that level. To give you some context, we currently sit at 80%, which nationally speaking is pretty strong, though there is room for improvement.
Ryan Langston
analystUnderstood. I'm familiar with the dialysis department.
Javier Rodriguez
executiveRight. The sole additional item I would mention is that flu vaccines rise during Q4 compared with Q3, and that pushes up RPT somewhat along with some cost. Therefore, that also plays a role in the Q4 versus Q3 RPT pattern.
Ryan Langston
analystYeah, that's clear. Then, only one more item. I realize the dialysis group differs somewhat from the individual MA group, but assuming that kind of unchanged advance notice applies to 2027 and the final notice, I suppose, could there be any perhaps just directional shift in what we might expect regarding growth outlook for 2027? Thanks.
Joel Ackerman
executiveYeah. Appreciate the question, Ryan. Something worth pointing out is that the ESRD group has a separate funding pool within MA, and CMS has in fact recognized an underfunding existed, so a catch-up occurred. Thus, the dialysis or ESKD group is going to get a 6% increase in 2027, which, from where we sit, mirrors the reality and would leave an MA plan inclined to want to bring these patients into the risk pool.
Javier Rodriguez
executiveRyan, what I'd tack onto that is this: it isn't just that reimbursement works differently — the entire coding system operates under different rules. That means things like V28, rebasing, and greater coding intensity for a particular year either don't factor into the ESRD MA rate calculation at all, or they play a far smaller role in it. And the notice that came out last week makes all of that clear too. Everything is laid out explicitly.
Ryan Langston
analystAll right. Thank you.
Javier Rodriguez
executiveThank you.
Javier Rodriguez
executiveThanks, Michelle, and thanks to everyone for being here. I hope it's completely obvious that our enthusiasm and excitement regarding clinical possibilities are truly through the roof when it comes to improving the lives of the people we treat. There's a strong alignment between what we aim to achieve clinically and what we aim to achieve financially. When we carry out our mission of providing the finest care to those we treat, we're also able to generate returns for those who hold our stock. I appreciate your attention, and I appreciate you being on this call today. Enjoy the rest of your day.
Operator
operatorThanks. That wraps up the conference call for today. At this point, you're welcome to go ahead and disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.